Interferon toxicity worse in retrospect; impact on Q-TWiST? Quality-Adjusted Time Without Symptoms or Toxicity

Comment

D L Longo. J Clin Oncol. 1998 Nov.

. 1998 Nov;16(11):3716; author reply 3718.

No abstract available

Comment on

Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.
Solal-Céligny P, Lepage E, Brousse N, Tendler CL, Brice P, Haïoun C, Gabarre J, Pignon B, Tertian G, Bouabdallah R, Rossi JF, Doyen C, Coiffier B. Solal-Céligny P, et al. J Clin Oncol. 1998 Jul;16(7):2332-8. doi: 10.1200/JCO.1998.16.7.2332. J Clin Oncol. 1998. PMID: 9667247 Clinical Trial.
Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making.
Cole BF, Solal-Céligny P, Gelber RD, Lepage E, Gisselbrecht C, Reyes F, Sebban C, Sugano D, Tendler C, Goldhirsch A. Cole BF, et al. J Clin Oncol. 1998 Jul;16(7):2339-44. doi: 10.1200/JCO.1998.16.7.2339. J Clin Oncol. 1998. PMID: 9667248
Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma.
Zee B, Cole B, Li T, Browman G, James K, Johnston D, Sugano D, Pater J. Zee B, et al. J Clin Oncol. 1998 Aug;16(8):2834-9. doi: 10.1200/JCO.1998.16.8.2834. J Clin Oncol. 1998. PMID: 9704736